Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2006-12-19
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S380000, C514S407000, C514S406000, C548S143000, C548S246000, C548S364100, C548S375100
Reexamination Certificate
active
07151113
ABSTRACT:
The present invention provides pyrazole derived compounds of formula (I)useful for treating p38 kinase-associated conditions, where W, X, R1, R2, R3, R4, R5, R6and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
REFERENCES:
patent: 4200750 (1980-04-01), Warner, Jr. et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6706711 (2004-03-01), Hale
patent: 6706720 (2004-03-01), Atwal et al.
patent: 2002/0065270 (2002-05-01), Moriarty et al.
patent: 2002/0137747 (2002-09-01), Moriarty et al.
patent: 2003/0139435 (2003-07-01), Ahmed et al.
patent: 2004/0039033 (2004-02-01), Atwal et al.
patent: WO 02/062804 (2002-08-01), None
patent: WO02/096905 (2002-12-01), None
patent: WO 2003037274 (2003-05-01), None
Chang et al., “Substituted Imidazoles as Glucagon Receptor Antagonists,” Bioorg. Med. Chem. Lett., 11 (2001) 2549-2553.
Klunge et al., “Radical Reactions of N-Heterocyclic Compounds, XV(1)”, Monatschefte fuer Chemie (1997), 128 (3) 261-270.
Ahn, H.-S. et al., “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”, J. Med. Chem., vol. 40, No. 14, pp. 2196-2210 (1997).
Greene, T.W. et al., Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., publ., pp. xi-xii (table of contents) (1999).
Henry, J.R. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24, No. 12, pp. 1345-1354 (1999).
Manning, G. et al., “The Protein Kinase Complement of the Human Genome”, Science, vol. 298, pp, 1912-1916, 1933-1934 (2002).
Moreland, L.W. et al., “Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial”, Ann. Intern. Med., vol. 130, No. 6, pp. 478-486 (1999).
Raingeaud, J. et al., “MKK3- and MKK6-Regulated Gene Expression Is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Cellular Biology, vol. 16, No. 3, pp. 1247-1255 (1996).
Rankin, E.C.C. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, No. 4, pp. 334-342 (1995).
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, No. 9, pp. 807-823 (1999).
Das Jagabandhu
Dyckman Alaric J.
Leftheris Katerina
Liu Chunjian
Moquin Robert V.
Bristol Myers Squibb Company
Grazier Nyeemah
Saeed Kamal A.
Wang Joseph C.
Winslow Anastasia P.
LandOfFree
Pyrazole-amine compounds useful as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole-amine compounds useful as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole-amine compounds useful as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683589